M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal Pharmaceutical Business ReviewThe deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments.OncologyRead full story pharminent July 6, 2026 (Last updated: July 6, 2026) Pharmaceutical Business Review The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. Oncology Read full story Post navigation Previous: Roche looks to Astex in $515m breast cancer dealNext: Novartis Acquires UK ADC Specialist Myricx Bio for Up to $1.5 Billion Related Stories M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026 M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
